New Pharmacologic Approaches to Bronchopulmonary Dysplasia

An update on pharmacologic approaches to bronchopulmonary dysplasia.

Bronchopulmonary dysplasia (BPD) is the most prevalent long-term morbidity in surviving extremely preterm infants and is linked to increased risk of reactive airways disease, pulmonary hypertension, post-neonatal mortality, and adverse neurodevelopmental outcomes. BPD affects approximately 20% of premature newborns, and up to 60% of premature infants born before completing 26 weeks of gestation...

Current Pharmacologic Approaches for Prevention and Treatment of Bronchopulmonary Dysplasia

Bronchopulmonary dysplasia (BPD) is a major complication of preterm birth and has serious adverse long-term health consequences. The etiology of BPD is complex, multifactorial, and incompletely understood. Contributing factors include ventilator-induced lung injury, exposure to toxic oxygen levels, and infection. Several preventive and therapeutic strategies have been developed with variable su...

Bronchopulmonary dysplasia: old problem, new presentation.

Bronchopulmonary dysplasia: a new look at management.

Bronchopulmonary dysplasia is an unacceptable but, at present, seemingly unavoidable complication of neonatal intensive care. There are many theories as to why this disorder arises, including lung immaturity, barotrauma from positive airway pressure ventilation, oxygen toxicity, respiratory infections after intubation, and increased lung fluid. Definitions vary, but based on the physiological d...

Bronchopulmonary Dysplasia

Bronchopulmonary dysplasia (BPD) continues to be the most common and most important complication in preterm infants with RDS. The incidence varies from 20 to 60 % in preterm infants whose weight are < 1500 gram. The presence of BPD is often associated with significant mortality and short term and long term morbidity, including growth failure and neurodevelopment delay. The exact mechanism and p...